Search results
Added:
1 year ago
ESC-HFA 23 - Dr Jawad Haider Butt (Copenhagen University Hospital, DK) outlines the findings of a patient-level meta-analysis of the DAPA-HF and DELIVER trials, which studied the safety and effectiveness of dapagliflozin on patients with both peripheral arterial disease and heart failure. These trials covered the spectrum of patients with heart failure.
The findings of this meta-analysis suggest…
View more
Added:
2 years ago
ESC-HFA 23 –Dr Ross Campbell (University of Glasgow, UK)joins us onsite to discuss the findings of the DAPA-RESIST Trial, which aimed to assess the affect of dapagliflozin as compared to metolazone in heart failure patients with diuretic resistance (NCT04860011).
In this phase 3 trial, investigators studied whether SGLT2i led to greater diuresis in this patient group, as to the standard practice…
View more
Added:
1 year ago
AHA 2023 — Investigator, Prof Stefan James, Prof Jonas Oldgren (Uppsala University, SE) and Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) discuss the findings of the DAPA-MI trial (NCT04564742).This multicenter, parallel-group, registry-based, randomized, double-blind and placebo-controlled phase 3 trial (AstraZeneca) investigated the effect of dapagliflozin 10 mg vs placebo…
View more
Added:
2 years ago
ESC-HFA 2023 — Prof Domingo Pascual Figal (Hospital Clinico Universitario Virgen de la Arrixaca, SP) discusses the DAPA MODA study (NCT04707352).
The study aimed to assess the effects of dapagliflozin on cardiac remodeling parameters, particularly LA geometry and function, and biomarkers reflecting pathophysiological pathways. Findings from ESC Heart Failure 2023 revealed that dapagliflozin…
View more
Added:
2 years ago
ESC-HFA 2023 - Dr Ankeet Bhatt (Kaiser Permanante San Francisco Medical Center, US) joins us onsite to discuss a study that looked into Kansas City Cardiomyopathy Questionnaire (KCCQ) scores in patients with varying ejection fractions, that were enrolled in the DELIVER and DAPA-HF trials.
This study used pooled, patient-level data from the DAPA-HF and DELIVER studies, aiming to examine the…
View more
Added:
1 year ago
What's hot at #AHA23?Join Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) as they review the late-breaking science data from AHA Scientific Sessions 2023.They interpret the evidence from five key trials, providing context, asking thought-provoking questions to translate the data into key take-home messages for practice and research.Trials Covered00:20 - DAPA…
View more
Added:
1 year ago
What should you keep an eye out for at this year's AHA Scientific Sessions?Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, NL) return with their 'View from the Thoraxcenter' preview to highlight late-breaking and featured science trials being presented at this year's AHA Scientific Sessions. Join this dynamic discussion on some of the most anticipated data releases.The…
View more
Added:
1 year ago
Added:
1 year ago
ESC-HFA 2023 – Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) joined by Dr James Januzzi (Massachusetts General Hospital, US) to discuss late-breaking science highlights of this year's ESC Heart Failure.
Trials covered in details include:
1:13: First-in-Human Study of NI006 in Patients With Amyloid Transthyretin Cardiomyopathy
1:42: TRACER-HF:Trientine-HCL for treatment of…
View more
Added:
1 year ago
Stay up-to-date with the latest data in cardiovascular science with the help of renowned experts and emerging voices who offer concise summaries, in-depth discussions, and critical reviews to keep you informed.In their regular View from the Thoraxcenter series, Prof Van Mieghem and Dr Daemen provide valuable insights into the most anticipated trials of AHA 23. With their keen awareness of…
View more
